Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.
The Sussex, England-based biotechnology company said the.
Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.
Shares in the Sussex-based biotechnology company specialising in allergy vaccines were suspended.
Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.
The Sussex-based biotechnology.
The following stocks are the leading risers and fallers on AIM in London on Wednesday.
AIM - WINNERS
Impellam Group PLC, up 26% at 819.12 pence, 12-month range 580.00p-950.00p..